help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaillard, R. C.
Right arrow Articles by Saurat, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaillard, R. C.
Right arrow Articles by Saurat, J. H.

Journal of Clinical Endocrinology & Metabolism, Vol 61, 1009-1011, Copyright © 1985 by Endocrine Society


ARTICLES

RU 486 inhibits peripheral effects of glucocorticoids in humans

RC Gaillard, D Poffet, AM Riondel and JH Saurat

RU 486 [17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)17 alpha-(prop-1- ynyl)estra-4,9-dien-3-one] is a synthetic steroid receptor antagonist. To evaluate the peripheral antiglucocorticoid action of this compound, we investigated its ability to antagonize cutaneous steroid-induced vasoconstriction. This phenomenon, produced by three different topical steroids in six normal men, was consistently and significantly attenuated or abolished by oral administration of 6 mg/kg RU 486. This demonstration of a peripheral action of RU 486 is important in relation to the potential therapeutic use of this well tolerated drug in states of hypercortisolism. It also indicates that the cutaneous vasoconstrictor effects of topical steroids are mediated by occupancy of glucocorticoid receptors.


This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
B. R Walker
Glucocorticoids and Cardiovascular Disease
Eur. J. Endocrinol., November 1, 2007; 157(5): 545 - 559.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
S. Johanssen and B. Allolio
Mifepristone (RU 486) in Cushing's syndrome
Eur. J. Endocrinol., November 1, 2007; 157(5): 561 - 569.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. Livingston, R. Chaudhuri, A. D. McMahon, I. Fraser, C. P. McSharry, and N. C. Thomson
Systemic sensitivity to corticosteroids in smokers with asthma
Eur. Respir. J., January 1, 2007; 29(1): 64 - 71.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. Chaudhuri, E. Livingston, A. D. McMahon, J. Lafferty, I. Fraser, M. Spears, C. P. McSharry, and N. C. Thomson
Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with Asthma
Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 127 - 133.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
P. Lalitkumar, J Sengupta, and D Ghosh
Endometrial tumor necrosis factor {alpha} (TNF{alpha}) is a likely mediator of early luteal phase mifepristone-mediated negative effector action on the preimplantation embryo
Reproduction, March 1, 2005; 129(3): 323 - 335.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
O. Heikinheimo, T. Raivio, H. Honkanen, S. Ranta, and O. A. Janne
Termination of Pregnancy with Mifepristone and Prostaglandin Suppresses Transiently Circulating Glucocorticoid Bioactivity
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 323 - 326.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Xiao, X. Huang, S. Bae, C. A. Ducsay, and L. Zhang
Cortisol-mediated potentiation of uterine artery contractility: effect of pregnancy
Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H238 - H246.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
B. R. Walker, D. I.W. Phillips, J. P. Noon, M. Panarelli, R. Andrew, H. V. Edwards, D. W. Holton, J. R. Seckl, D. J. Webb, and G. C. M. Watt
Increased Glucocorticoid Activity in Men With Cardiovascular Risk Factors
Hypertension, April 1, 1998; 31(4): 891 - 895.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
B. R. Walker, R. Best, C. H.L. Shackleton, P. L. Padfield, and C. R.W. Edwards
Increased Vasoconstrictor Sensitivity to Glucocorticoids in Essential Hypertension
Hypertension, February 1, 1996; 27(2): 190 - 196.
[Abstract] [Full Text]


Home page
NEJMHome page
I. M. Spitz and C.W. Bardin
Mifepristone (RU 486) -- A Modulator of Progestin and Glucocorticoid Action
N. Engl. J. Med., August 5, 1993; 329(6): 404 - 412.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society